Data analytics platform developer Starburst raised $250m in a Salesforce-backed round valuing it above $3.3bn while SoftBank co-led a $140m round for small molecule drug developer Ventus.

Funding

Enterprise software producer Salesforce took part in a $250m series D round for US-headquartered data analytics software provider Starburst yesterday through subsidiary Salesforce Ventures. Investment adviser Alkeon Capital Management led the round, which valued the company at $3.35bn and which also featured Altimeter Capital Management, B Capital Group, Andreessen Horowitz, Coatue Management and Index Ventures.

Canada-based small molecule drug developer Ventus Therapeutics completed a $140m series C round yesterday co-led by telecommunications and internet group SoftBank’s Vision Fund 2,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn